ROCKVILLE, Md., March 9, 2015 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific
therapies for serious infections and diseases, with a focus on
protecting the microbiome, announced today that the
Company intends to release its financial results for the year ended
December 31, 2014 on Monday, March 16, 2015. The Company will also
hold an investor conference call on Monday,
March 16th, at 8:30 a.m.
EDT.
During the call, Jeffrey Riley,
Synthetic Biologics' Chief Executive Officer, will provide an
update on the Company's C. difficile prevention,
constipation-predominant irritable bowel syndrome (C-IBS),
Pertussis (whooping cough) and multiple sclerosis (MS) programs.
C. Evan Ballantyne, Synthetic
Biologics' Chief Financial Officer, will review the Company's
financial results for the year ended December 31, 2014.
Interested parties should call 1-888-347-5280 (U.S. toll free),
1-855-669-9657 (Canada toll free),
or +1 412-902-4280 (International), fifteen minutes before the
start of the call to register. Registered callers on the toll free
line may ask to be placed in the queue for the Question &
Answer Session. The call will also be webcast over the Internet at
http://www.videonewswire.com/event.asp?id=101639. If you are unable
to participate during the live conference call, the webcast will be
available for replay at the same URL,
http://www.videonewswire.com/event.asp?id=101639, for 30 days after
the call.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage
biotechnology company developing pathogen-specific therapies for
serious infections and diseases, with a focus on protecting the
microbiome. The Company is developing an oral biologic to protect
the gut microbiome from intravenous (IV) antibiotics for the
prevention of C. difficile infection, an oral statin
treatment to reduce the impact of methane producing organisms on
constipation-predominant irritable bowel syndrome (C-IBS), and in
collaboration with Intrexon Corporation (NYSE: XON), a monoclonal
antibody combination for the treatment of Pertussis. In addition,
the Company is developing a Phase 2 oral estriol drug for the
treatment of relapsing-remitting multiple sclerosis (MS) and
cognitive dysfunction in MS. For more information, please visit
Synthetic Biologics' website at www.syntheticbiologics.com.
Logo -
http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-report-year-end-2014-financial-results-300046866.html
SOURCE Synthetic Biologics, Inc.